

Henri-Jean Aubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5556285/publications.pdf>

Version: 2024-02-01

107
papers

4,718
citations

145106

33
h-index

116156

66
g-index

114
all docs

114
docs citations

114
times ranked

6079
citing authors

#	ARTICLE	IF	CITATIONS
1	Attitudes & behaviors toward the management of tobacco smoking patients: qualitative study with French primary care physicians. , 2022, 23, 10.		2
2	Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology, 2022, 36, 1136-1145.	2.0	5
3	Experimenting first with e-cigarettes versus first with cigarettes and transition to daily cigarette use among adolescents: the crucial effect of age at first experiment. Addiction, 2021, 116, 1521-1531.	1.7	11
4	Association of smoking reduction and mortality: protocol for a systematic review and meta-analysis of longitudinal observational studies. BMJ Open, 2021, 11, e039483.	0.8	2
5	The Efficacy of Primavera, a Prevention Programme on Alcohol and Tobacco Use among 10-12-Year-Old Schoolchildren: A Randomized Controlled Cluster Study. International Journal of Environmental Research and Public Health, 2021, 18, 3852.	1.2	4
6	Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis. Alcohol and Alcoholism, 2021, 56, 545-555.	0.9	2
7	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy. Alcoholism: Clinical and Experimental Research, 2021, 45, 1722-1734.	1.4	12
8	Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology, 2021, 52, 18-30.	0.3	13
9	France Grants an Approval to Baclofen for Alcohol Dependence. Alcohol and Alcoholism, 2020, 55, 44-45.	0.9	13
10	“The post-COVID era” challenges in the treatment of substance use disorder (SUD) after the pandemic. BMC Medicine, 2020, 18, 241.	2.3	44
11	Tobacco smoking: the likely confounder of the association between heart diseases and suicide. Journal of Internal Medicine, 2020, 288, 605-606.	2.7	2
12	Characteristics of Gamblers Who Use the French National Problem Gambling Helpline and Real-Time Chat Facility: Longitudinal Observational Study. JMIR Formative Research, 2020, 4, e13388.	0.7	5
13	Passive smoking in childhood increases the risk of developing rheumatoid arthritis. Rheumatology, 2019, 58, 1154-1162.	0.9	39
14	Feasibility, acceptability and preliminary outcomes of a mindfulness-based relapse prevention program in a naturalistic setting among treatment-seeking patients with alcohol use disorder: a prospective observational study. BMJ Open, 2019, 9, e026839.	0.8	14
15	RE: “ASSOCIATION BETWEEN REDUCTIONS OF NUMBER OF CIGARETTES SMOKED PER DAY AND MORTALITY AMONG OLDER ADULTS IN THE UNITED STATES” American Journal of Epidemiology, 2019, 188, 1756-1757.	1.6	1
16	Quality of life instruments used in problem gambling studies: A systematic review and a meta-analysis. Neuroscience and Biobehavioral Reviews, 2019, 104, 58-72.	2.9	6
17	Giving room to subjectivity in understanding and assessing problem gambling: A patient-centered approach focused on quality of life. Journal of Behavioral Addictions, 2019, 8, 103-113.	1.9	7
18	Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth. JAMA Psychiatry, 2019, 76, 766.	6.0	0

#	ARTICLE	IF	CITATIONS
19	Cognitive training: A new avenue in gambling disorder management?. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 106, 227-233.	2.9	13
20	Medication Development: Reducing Casualties in the Valley of Death and Providing Support for Survivors. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 22-25.	1.4	1
21	Health-related quality of life in alcohol dependence: Similar cross-cultural impact beyond specific drinking habits. <i>Journal of Ethnicity in Substance Abuse</i> , 2019, 18, 279-295.	0.6	2
22	Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144) Tj ETQq0 0 QrgBT /Overlock 10 T	2.1	48
23	Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. <i>Addiction Biology</i> , 2018, 23, 291-303.	1.4	31
24	Description and assessment of trustability of motives for self-exclusion reported by online poker gamblers in a cohort using account-based gambling data. <i>BMJ Open</i> , 2018, 8, e022541.	0.8	10
25	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. <i>Lancet Psychiatry</i> , 2018, 5, 957-960.	3.7	94
26	Alcohol consumption, drinker identity, and quality of life among students: why there cannot be one prevention strategy for all. <i>Quality of Life Research</i> , 2018, 27, 2629-2637.	1.5	1
27	Comment on the Association of Hormonal Contraception With Suicide Attempts and Suicides. <i>American Journal of Psychiatry</i> , 2018, 175, 683-683.	4.0	1
28	Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. <i>Addiction Biology</i> , 2018, 23, 969-986.	1.4	59
29	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. <i>Frontiers in Psychiatry</i> , 2018, 9, 708.	1.3	47
30	A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patientsâ€”The ALPADIR Study. <i>Alcohol and Alcoholism</i> , 2017, 52, 439-446.	0.9	112
31	Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?. <i>European Addiction Research</i> , 2017, 23, 219-230.	1.3	67
32	E-Cigarettes and Toxin Exposure. <i>Annals of Internal Medicine</i> , 2017, 167, 524.	2.0	1
33	Can reduced drinking be a viable goal for alcohol dependent patients?. <i>World Psychiatry</i> , 2017, 16, 325-326.	4.8	16
34	Associations between substance use disorders and suicide mortality risk should be adjusted for tobacco use disorder. <i>Addiction</i> , 2017, 112, 2066-2066.	1.7	2
35	Neuropsychological Impairment in Detoxified Alcohol-Dependent Subjects with Preserved Psychosocial Functioning. <i>Frontiers in Psychiatry</i> , 2017, 8, 193.	1.3	4
36	Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. <i>BMC Medicine</i> , 2017, 15, 173.	2.3	24

#	ARTICLE	IF	CITATIONS
37	The Role of General Practitioners in the 2015 French Guidelines on Alcohol Misuse. <i>Alcohol and Alcoholism</i> , 2017, 52, 747-748.	0.9	2
38	Validation of a new patient-reported outcome instrument of health-related quality of life specific to patients with alcohol use disorder: the Alcohol Quality of Life Scale (AQoLS). <i>Quality of Life Research</i> , 2016, 25, 1549-1560.	1.5	15
39	Letter by Aubin et al Regarding Article, "Association of Coffee Consumption with Total and Cause-Specific Mortality in 3 Large Prospective Cohorts", <i>Circulation</i> , 2016, 133, e659.	1.6	0
40	The 2015 French guidelines on alcohol misuse, issued in partnership with the European Federation of Addiction Societies: a focus on children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2016, 25, 1145-1148.	2.8	6
41	A Point-by-Point Response to Brailion. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 537-538.	1.9	0
42	Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 25-37.	1.9	91
43	The role of alcohol in the management of hypertension in patients in European primary health care practices "a survey in the largest European Union countries. <i>BMC Family Practice</i> , 2016, 17, 130.	2.9	24
44	Opioid analgesics. <i>Lancet</i> , The, 2016, 388, 656.	6.3	1
45	Students worry about the impact of alcohol on quality of life: Roles of frequency of binge drinking and drinker self-concept. <i>Drug and Alcohol Dependence</i> , 2016, 167, 42-48.	1.6	29
46	Tobacco use is associated with increased plasma BDNF levels in depressed patients. <i>Psychiatry Research</i> , 2016, 246, 370-372.	1.7	16
47	Tracking online poker problem gamblers with player account-based gambling data only. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 333-342.	1.1	26
48	The Efficacy of Three Modalities of Internet-Based Psychotherapy for Non-Treatment-Seeking Online Problem Gamblers: A Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2016, 18, e36.	2.1	49
49	Smoking and Suicide Mortality Risk in Alcohol-Dependent Individuals. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e906-e906.	1.1	3
50	Smoking as a confounder of the association of suicidality with serum lipid levels. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E24.1-E24.	1.4	2
51	The New French Guidelines on Alcohol Misuse: An Initiative for Strengthening Cross-European Interplay. <i>Addiction</i> , 2015, 110, 1362-1363.	1.7	8
52	Smoker's identity scale: Measuring identity in tobacco dependence and its relationship with confidence in quitting. <i>American Journal on Addictions</i> , 2015, 24, 607-612.	1.3	21
53	Feeding Two Birds with One Stone: The Case of Varenicline. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2299-2301.	1.4	3
54	People with Alcohol Use Disorders in Specialized Care in Eight Different European Countries. <i>Alcohol and Alcoholism</i> , 2015, 50, 310-318.	0.9	45

#	ARTICLE	IF	CITATIONS
55	Development of the Alcohol Quality of Life Scale (AQoLS): a new patient-reported outcome measure to assess health-related quality of life in alcohol use disorder. <i>Quality of Life Research</i> , 2015, 24, 1471-1481.	1.5	25
56	Clinical Relevance of As-Needed Treatment with Nalmefene in Alcohol-Dependent Patients. <i>European Addiction Research</i> , 2015, 21, 160-168.	1.3	31
57	Re: "Coffee Consumption and Mortality From all Causes, Cardiovascular Disease, and Cancer: A Dose-Response Meta-Analysis". <i>American Journal of Epidemiology</i> , 2015, 181, 734-735.	1.6	0
58	The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients. <i>PLoS ONE</i> , 2015, 10, e0129289.	1.1	24
59	Self-medication of achalasia with cannabis, complicated by a cannabis use disorder. <i>World Journal of Gastroenterology</i> , 2015, 21, 6381.	1.4	3
60	Acute and Long-Term Effects of Cannabis Use: A Review. <i>Current Pharmaceutical Design</i> , 2014, 20, 4112-4118.	0.9	200
61	Wim van den Brink and colleagues reply to Des Spence and Alain Braillon. <i>BMJ, The</i> , 2014, 348, g2605-g2605.	3.0	4
62	Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene. <i>Patient Preference and Adherence</i> , 2014, 8, 1347.	0.8	14
63	Spirituality and Religion Among French Prisoners. <i>International Journal of Offender Therapy and Comparative Criminology</i> , 2014, 58, 821-834.	0.8	26
64	Cultural Adaptation of the Alcohol Quality of Life Scale for Use in Japan, China, and Korea. <i>Value in Health</i> , 2014, 17, A462.	0.1	2
65	Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 324-336.	1.1	103
66	Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e87366.	1.1	218
67	Off-Label Baclofen Prescribing Practices among French Alcohol Specialists: Results of a National Online Survey. <i>PLoS ONE</i> , 2014, 9, e98062.	1.1	41
68	Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1959-1967.	0.9	15
69	Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption. <i>Drug and Alcohol Dependence</i> , 2013, 133, 15-29.	1.6	46
70	Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies. <i>Alcohol and Alcoholism</i> , 2013, 48, 570-578.	0.9	293
71	The Economic Burden of Alcohol Dependence in Europe. <i>Alcohol and Alcoholism</i> , 2013, 48, 259-269.	0.9	80
72	Quantitative damage-benefit evaluation of drug effects: major discrepancies between the general population, users and experts. <i>Journal of Psychopharmacology</i> , 2013, 27, 590-599.	2.0	11

#	ARTICLE	IF	CITATIONS
73	The Evolutionary Puzzle of Suicide. <i>International Journal of Environmental Research and Public Health</i> , 2013, 10, 6873-6886.	1.2	35
74	Alcohol dependence treatment in the EU: A literature search and expert consultation about the availability and use of guidelines in all EU countries plus Iceland, Norway, and Switzerland. <i>The International Journal of Alcohol and Drug Research</i> , 2013, 2, 53-67.	0.9	22
75	Weight gain in smokers after quitting cigarettes: meta-analysis. <i>BMJ, The</i> , 2012, 345, e4439-e4439.	3.0	377
76	Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial. <i>Journal of Psychopharmacology</i> , 2012, 26, 1003-1009.	2.0	15
77	Ethyl Glucuronide for Detecting Alcohol Lapses in Patients With an Alcohol Use Disorder. <i>Journal of Addiction Medicine</i> , 2012, 6, 35-38.	1.4	7
78	Early Life Origins of Adult Disease and Maternal Smoking During Pregnancy. <i>American Journal of Public Health</i> , 2012, 102, e12-e12.	1.5	2
79	Increased risk of coronary heart disease in female smokers. <i>Lancet, The</i> , 2012, 379, 801.	6.3	1
80	Is Baclofen a Revolutionary Medication in Alcohol Addiction Management? Review and Recent Updates. <i>Substance Abuse</i> , 2012, 33, 336-349.	1.1	36
81	French-language version of the World Health Organization quality of life spirituality, religiousness and personal beliefs instrument. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 39.	1.0	26
82	Do Placebo Response Rates from Cessation Trials Inform on Strength of Addictions?. <i>International Journal of Environmental Research and Public Health</i> , 2012, 9, 192-211.	1.2	16
83	Smoking, quitting, and psychiatric disease: A review. <i>Neuroscience and Biobehavioral Reviews</i> , 2012, 36, 271-284.	2.9	198
84	Current Smoking, Hypoxia, and Suicide. <i>American Journal of Psychiatry</i> , 2011, 168, 326-327.	4.0	19
85	Pharmacotherapy for Smoking Cessation: Present and Future. <i>Current Pharmaceutical Design</i> , 2011, 17, 1343-1350.	0.9	35
86	Craving's place in addiction theory: Contributions of the major models. <i>Neuroscience and Biobehavioral Reviews</i> , 2010, 34, 606-623.	2.9	264
87	The French Observational Cohort of Usual Smokers (FOCUS) cohort: French smokers perceptions and attitudes towards smoking cessation. <i>BMC Public Health</i> , 2010, 10, 100.	1.2	35
88	Coalitional Affiliation Rather Than Religiosity Might Explain the Heritability of Church Attendance. <i>American Journal of Psychiatry</i> , 2010, 167, 215-216.	4.0	0
89	Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics. <i>Drug and Alcohol Dependence</i> , 2010, 112, 239-246.	1.6	18
90	Determinants of improvement in quality of life of alcohol-dependent patients during an inpatient withdrawal programme. <i>International Journal of Medical Sciences</i> , 2009, 6, 160-167.	1.1	51

#	ARTICLE	IF	CITATIONS
91	Factors Associated with Higher Body Mass Index, Weight Concern, and Weight Gain in a Multinational Cohort Study of Smokers Intending to Quit. <i>International Journal of Environmental Research and Public Health</i> , 2009, 6, 943-957.	1.2	30
92	Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. <i>European Journal of Public Health</i> , 2009, 19, 650-654.	0.1	43
93	Diffusion Tensor Tractography in Mesencephalic Bundles: Relation to Mental Flexibility in Detoxified Alcohol-Dependent Subjects. <i>Neuropsychopharmacology</i> , 2009, 34, 1223-1232.	2.8	79
94	Imaging of Language-Related Brain Regions in Detoxified Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 977-984.	1.4	23
95	Management of smoking cessation in patients with psychiatric disorders. <i>Current Medical Research and Opinion</i> , 2009, 25, 511-518.	0.9	79
96	Management of emergent psychiatric symptoms during smoking cessation. <i>Current Medical Research and Opinion</i> , 2009, 25, 519-525.	0.9	22
97	Episodic Memory in Detoxified Alcoholics: Contribution of Grey Matter Microstructure Alteration. <i>PLoS ONE</i> , 2009, 4, e6786.	1.1	59
98	Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. <i>Thorax</i> , 2008, 63, 717-724.	2.7	285
99	Brain Morphometry and Cognitive Performance in Detoxified Alcohol-Dependents with Preserved Psychosocial Functioning. <i>Neuropsychopharmacology</i> , 2007, 32, 429-438.	2.8	358
100	Comparison of the effects of a 24-hour nicotine patch and a 16-hour nicotine patch on smoking urges and sleep. <i>Nicotine and Tobacco Research</i> , 2006, 8, 193-201.	1.4	24
101	Description of tobacco addiction in pregnant women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005, 120, 146-151.	0.5	30
102	The Modified Reasons for Smoking Scale: factorial structure, gender effects and relationship with nicotine dependence and smoking cessation in French smokers*. <i>Addiction</i> , 2003, 98, 1575-1583.	1.7	125
103	Traitement de la dépendance aux substances psycho-actives. <i>Annales Medico-Psychologiques</i> , 2003, 161, 556-562.	0.2	1
104	Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation. <i>Drugs</i> , 2002, 62, 45-52.	4.9	74
105	Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. <i>Addiction</i> , 2002, 97, 1347-1354.	1.7	42
106	Changes in cigarette smoking and coffee drinking after alcohol detoxification in alcoholics. <i>Addiction</i> , 1999, 94, 411-416.	1.7	26
107	Joint influence of alcohol, tobacco, and coffee on biological markers of heavy drinking in alcoholics. <i>Biological Psychiatry</i> , 1998, 44, 638-643.	0.7	19